WASHINGTON – The FDA will collaborate with the Reagan-Udall Foundation to host a public meeting titled “Advancing Treatments for Post-Traumatic Stress Disorder (PTSD)” on September 6, 2024.
This meeting aims to support the agency’s focus on understanding the medical need for PTSD treatment and facilitating treatment development.
The public meeting will offer both virtual and in-person attendance options. It will include a panel discussion with federal partners to explore efforts to accelerate treatment development for PTSD, including psychedelic drug development.
People with lived PTSD experience, such as veterans, family members, and patient advocates, as well as researchers, scientists, and drug developers, will have the opportunity to provide public comment. Up to thirty stakeholders will have three minutes to present public comments virtually or in person.
The deadline to request to present stakeholder comments is Noon (ET) on September 3, 2024. Speakers will be notified by September 4. Those interested in attending the public session must register through the Reagan-Udall Foundation. Instructions for attending in person and/or accessing the live webcast of the public meeting will be provided to all registrants before the event. The meeting agenda, additional materials, and any updates will be posted on the Reagan-Udall Foundation website.
